AR and prostate cancer: Metabolites related to phospholipid metabolism, including glycerophosphorylcholine (GPC) and glycerophosphoethanolamine, were observed to decrease in the castration-resistant prostate cancer cells following treatment with androgen receptor (AR) activation inhibitors (30).